EUVIMEDEUVIMED entdecken
Crossref

Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis

Arpan Mohanty iD, Yin Wang iD, Charles Stoecker

Obesity · 2025-10 · 33 (10) · 1845-1848

DOI: 10.1002/oby.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 13.08.2025. Verfasst von Arpan Mohanty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Obesity, Liver Cirrhosis, Mass Screening. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The study aimed to compare the cost‐effectiveness of various strategies for screening for MASLD‐related advanced hepatic fibrosis (fibrosis stage > 2) using the fibrosis‐4 index (FIB‐4) and liver stiffness measurement (LSM) by transient elastography (TE) in persons with obesity.

Methods

We created a decision‐analytic model comparing three screening strategies: no screening, TE, and FIB‐4 followed by TE. We used a Markov transition model to track liver state, with prevalence and transition probabilities specific to the population with obesity. If MASLD was detected, patients were treated with resmetirom.

Results

We found an incremental cost‐effectiveness ratio (ICER) of $234,781 (95% CI: $232,581, $235,608) when comparing TE to no screening with a 10‐year interval. We note the ICER of $234,673 (95% CI: $234,033, $235,072) when comparing TE to FIB‐4+TE. In multivariate simulations, we found no screening was most likely to be cost‐effective for willingness‐to‐pay for QALY below approximately $250,000.

Conclusions

Our results suggest routine screening for MASLD in obesity clinics is not cost‐effective with resmetirom as the available treatment. A prescreening with FIB‐4 before TE did not increase economic efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityLiver CirrhosisMass ScreeningHumansCost-Benefit AnalysisElasticity Imaging TechniquesMaleFemaleMiddle AgedMarkov ChainsAdultDecision Support TechniquesCost-Effectiveness Analysis

Stichwörter der Autor:innen

FIB‐4MASLDTEclinically significant liver fibrosisobesityscreening

Autor:innen und Institutionen

  • Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.

ORCID-Profile: Arpan Mohanty, Yin Wang

Förderung

  • Gilead Sciences

Zitieren

APA

Mohanty, A., Wang, Y., & Stoecker, C. (2025). Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity, 33(10), 1845-1848. https://doi.org/10.1002/oby.70005

Vancouver

Mohanty A, Wang Y, Stoecker C. Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity. 2025;33(10):1845-1848. doi:10.1002/oby.70005

BibTeX
@article{Mohanty2025,
  author = {Mohanty, Arpan and Wang, Yin and Stoecker, Charles},
  title = {Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {10},
  pages = {1845--1848},
  doi = {10.1002/oby.70005}
}
Kostenlos starten →